- Home
- AMZE vs ABP Comparison
AMZE vs ABP Comparison
Compare AMZE & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMZE | ABP |
|---|---|---|
| Founded | 2019 | 2004 |
| Country | United States | United States |
| Employees | 4 | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.3M | 12.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | AMZE | ABP |
|---|---|---|
| Price | $0.38 | $0.52 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | 1.4M | ★ 3.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6,741.66 | N/A |
| Revenue Next Year | $100.61 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.24 | $0.17 |
| 52 Week High | $11.76 | $7.34 |
Technical Indicators
Market Signals| Indicator | AMZE | ABP |
|---|---|---|
| Relative Strength Index (RSI) | 47.35 | 23.69 |
| Support Level | $0.34 | $0.19 |
| Resistance Level | $0.42 | $2.89 |
| Average True Range (ATR) | 0.05 | 0.28 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 61.93 | 0.21 |
Price Performance
Historical ComparisonAbout AMZE Amaze Holdings Inc.
Amaze Holdings Inc is a software company dedicated to empowering creators by providing comprehensive software solutions and services that facilitate e-commerce, social commerce, integrated commerce selling experiences, and the distribution of a premium wine brand. The group offers an end-to-end, creator-powered commerce platform offering tools for seamless product creation, modern e-commerce solutions, and scalable managed services.
About ABP Abpro Holdings Inc
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.